{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:01:31Z","timestamp":1786464091994,"version":"build-2736575974"},"reference-count":123,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The management of oligometastatic disease has undergone a significant paradigm shift over the past two decades. Once considered uniformly incurable, selected patients with metastatic disease can now achieve prolonged progression-free survival, durable disease control, and, in carefully selected cases, long-term remission or cure through metastasis-directed therapies. Advances in stereotactic ablative radiotherapy (SABR), surgery, systemic therapies, and the emerging concept of Curative Oligometastatic Radiotherapy (CORT) have challenged the traditional distinction between curative and palliative treatment. Concurrent developments in imaging, including PET\/CT, prostate-specific membrane antigen (PSMA) PET, whole-body MRI, and MR-guided adaptive radiotherapy (MR-linac), together with evolving biomarker research, are improving disease characterisation, refining patient selection, and treatment personalisation. As survival improves, an increasing number of patients are living with durably controlled metastatic cancer and experience long-term physical, psychological, cognitive, functional, and financial consequences of treatment. Despite these challenges, evidence-based survivorship pathways for patients with oligometastatic disease remain poorly defined. Supportive oncology is becoming an essential component of modern radiation oncology rather than an adjunct to cancer treatment. This emerging discipline focuses on optimising symptom control, minimising toxicity, and delivering structured survivorship care. Rather than being limited to end-of-life care, supportive oncology is embedded throughout the patient journey; from diagnosis and treatment selection to prehabilitation, rehabilitation, patient-reported outcome (PRO) monitoring, surveillance for late effects, multidisciplinary follow-up, and long-term survivorship. This review discusses how advances in precision radiotherapy, molecular imaging, biomarkers, and emerging treatment technologies are reshaping the management of oligometastatic disease while simultaneously creating a growing population of long-term survivors with increasingly complex supportive care needs. It highlights the expanding role of supportive oncology in the care of patients with oligometastatic disease, encompassing multidisciplinary symptom management and argues that improvements in disease control must now be matched by the development of evidence-based multidisciplinary survivorship pathways that integrate supportive oncology to optimise quality of life (QoL), functional independence, and patient-centred outcomes. Finally, this review highlights current evidence gaps and proposes future research priorities for developing evidence-based survivorship models for this rapidly expanding patient population.<\/jats:p>","DOI":"10.3390\/cancers18162584","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:46:16Z","timestamp":1786455976000},"page":"2584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surviving Cancer, Lacking Support: The Hidden Burden of Modern Radiation Oncology in the Treatment of Oligometastatic Disease"],"prefix":"10.3390","volume":"18","author":[{"given":"Beth","family":"Chasty","sequence":"first","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester M20 4BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2351-7179","authenticated-orcid":false,"given":"Agata","family":"Rembielak","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester M20 4BX, UK"},{"name":"Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Berman","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester M20 4BX, UK"},{"name":"Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2141-8313","authenticated-orcid":false,"given":"Eva","family":"Oldenburger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Leiden, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamaoncol.2026.0493","article-title":"Rethinking Treatment Intent Beyond the Curative\/Palliative Binary in Modern Oncology","volume":"12","author":"Henselmans","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"e12708","article-title":"Living with advanced cancer and the role of the primary care provider: The missing piece in the survivorship discourse","volume":"26","author":"Nekhlyudov","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","article-title":"New Strategies in Stereotactic Radiotherapy for Oligometastases","volume":"21","author":"Palma","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.21037\/apm.2020.03.31","article-title":"Oligometastases: History of a hypothesis","volume":"10","author":"Milano","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.semradonc.2023.07.001","article-title":"Advances and Challenges in Trials of Local Therapy for Patients with Oligometastatic or Oligoprogressive Disease","volume":"33","author":"Yan","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Izmailov, T., Ryzhkin, S., Borshchev, G., and Boichuk, S. (2023). Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials. Cancers, 15.","DOI":"10.3390\/cancers15215234"},{"key":"ref_12","first-page":"107","article-title":"Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy","volume":"40","author":"Niibe","year":"2010","journal-title":"Ultrasound Med. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261096","DOI":"10.1155\/2012\/261096","article-title":"Novel Insights of Oligometastases and Oligo-Recurrence and Review of the Literature","volume":"2012","author":"Niibe","year":"2012","journal-title":"Pulm. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Oka, R., Utsumi, T., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., Somoto, T., Kato, S., Endo, T., and Kamiya, N. (2024). Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches. Cancers, 16.","DOI":"10.3390\/cancers16030507"},{"key":"ref_15","first-page":"e78","article-title":"Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer","volume":"21","author":"Lee","year":"2022","journal-title":"Clin. Color. Cancer"},{"key":"ref_16","first-page":"40","article-title":"Management of oligoprogressive and oligopersistent disease in advanced NSCLC","volume":"23","author":"Ravella","year":"2025","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Santorsola, M., Circelli, L., Trotta, A.M., Izzo, F., Perri, F., Cascella, M., Sabbatino, F., Granata, V., and Correra, M. (2023). Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives. Cancers, 15.","DOI":"10.3390\/cancers15061827"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.neo.2024.101111","article-title":"Clinical and genetic drivers of oligo-metastatic disease in colon cancer","volume":"60","author":"Ottaiano","year":"2024","journal-title":"Neoplasia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/PPO.0000000000000438","article-title":"Prognostic and Predictive Biomarkers in Oligometastatic Disease","volume":"26","author":"Barnum","year":"2020","journal-title":"Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group","volume":"91","author":"Desouza","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"AlGhamdi, H., Dhont, J., Krayem, M., De Bruyn, P., Engels, B., Van Gestel, D., and Begin, R.V.D. (2022). The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease. Cancers, 14.","DOI":"10.3390\/cancers14082046"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1470-2045(16)30277-7","article-title":"Imaging oligometastatic cancer before local treatment","volume":"17","author":"Franklin","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.31793","article-title":"A risk-based approach to identifying oligometastatic disease on imaging","volume":"144","author":"Desouza","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-022-01879-3","article-title":"Steering decision making by terminology: Oligometastatic versus argometastatic","volume":"127","author":"Szturz","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_25","first-page":"100740","article-title":"Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications","volume":"5","author":"Jongbloed","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.22.01482","article-title":"Oligometastases: Emerging Evidence","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wujanto, C., Vellayappan, B., Siva, S., Louie, A.V., Guckenberger, M., Slotman, B.J., Onishi, H., Nagata, Y., Liu, M., and Lo, S.S. (2019). Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01219"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-022-01788-8","article-title":"A critical review on oligometastatic disease: A radiation oncologist\u2019s perspective","volume":"39","author":"Pacifico","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Ran-domized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, D., Zhao, Z., Zhao, W., Chen, G., Du, W., Li, Z., and Zhang, J. (2025). Surgery versus stereotactic body radiotherapy for oligometastatic colorectal cancer: A prospective cohort study with propensity score matching. BMC Cancer, 26.","DOI":"10.1186\/s12885-025-15448-3"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(21)00203-5","article-title":"Should stereotactic radiotherapy be the preferred treatment for oligometastatic disease?","volume":"22","author":"Palma","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gaito, S., Marvaso, G., Ortiz, R., Crellin, A., Aznar, M.C., Indelicato, D.J., Pan, S., Whitfield, G., Alongi, F., and Jereczek-Fossa, B.A. (2023). Proton Beam Therapy in the Oligometastatic\/Oligorecurrent Setting: Is There a Role? A Literature Review. Cancers, 15.","DOI":"10.3390\/cancers15092489"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.adro.2021.100690","article-title":"Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients with 1 to 3 Pulmonary Oligometastases From Various Primary Cancers","volume":"6","author":"Aibe","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.21037\/jgo-20-424","article-title":"Proton stereotactic body radiation therapy for liver metastases\u2014Results of 5-year experience for 81 hepatic lesions","volume":"12","author":"Coffman","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.14338\/IJPT-21-00014","article-title":"Proton Radiotherapy for Patients with Oligometastatic Breast Cancer Involving the Sternum","volume":"8","author":"Johnson","year":"2022","journal-title":"Int. J. Part. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13014-024-02419-4","article-title":"FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): Protocol for a prospective study of a novel radiotherapy approach","volume":"19","author":"Daugherty","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semradonc.2021.03.004","article-title":"Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers","volume":"31","author":"Morris","year":"2021","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_47","first-page":"419","article-title":"FLASH radiotherapy: Ultra-high dose rates to spare healthy tissue","volume":"96","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaoncol.2022.5843","article-title":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases","volume":"9","author":"Mascia","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2025.03.047","article-title":"Requirements and Study Design for the Next Proton FLASH Clinical Trials: An International Multidisciplinary Delphi Consensus","volume":"123","author":"Klaver","year":"2025","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chasty, B., Berman, R., Ahamed, A., Chow, E., Rembielak, A., and Oldenburger, E. (2026). Palliative Radiotherapy at the Crossroads of Supportive Oncology: Addressing Global Gaps, Guideline Deficits, and the Expanding Need for Symptom-Directed Cancer Care. Cancers, 18.","DOI":"10.3390\/cancers18040564"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2019.01.073","article-title":"A Current Review of Spatial Fractionation: Back to the Future?","volume":"104","author":"Billena","year":"2019","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_52","first-page":"101049","article-title":"Spatially fractionated radiotherapy for re-irradiation: Feasibility, safety, treatment planning, and outcomes","volume":"56","author":"Burns","year":"2025","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/j.semnuclmed.2024.05.011","article-title":"Combination Strategies and Targeted Radionuclide Therapies","volume":"54","author":"Jewell","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.semradonc.2025.04.003","article-title":"Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination with EBRT","volume":"35","author":"Civan","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2025.10.002","article-title":"Unlocking New Therapeutic Strategies in Oligometastatic Prostate Cancer with Radioligand and Metastasis-directed Radiation Therapy","volume":"82","author":"Cozzi","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.125.270465","article-title":"Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment","volume":"66","author":"Teunissen","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_57","first-page":"e240001","article-title":"Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT","volume":"4","author":"Nunez","year":"2024","journal-title":"Endocr. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tipsro.2022.04.005","article-title":"First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac","volume":"22","author":"Janssen","year":"2022","journal-title":"Tech. Innov. Patient Support. Radiat. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lee, K.N., Intven, M., Alongi, F., and Huynh, M.A. (2024). Clinical Applications of MR-Linac in Oligometastatic Disease. A Practical Guide to MR-Linac, Springer.","DOI":"10.1007\/978-3-031-48165-9_12"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2022.05.016","article-title":"Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Abdominopelvic Oligometastases","volume":"114","author":"Yang","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semradonc.2023.10.013","article-title":"MRI-Guided Adaptive Radiation Therapy","volume":"34","author":"Benitez","year":"2023","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2022.06.076","article-title":"Finding Resonance: Using MRI to Improve the Care of Oligometastatic Disease","volume":"114","author":"Singer","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20200042","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: From a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.medj.2023.02.003","article-title":"The abscopal effect in patients with cancer receiving immunotherapy","volume":"4","author":"Nelson","year":"2023","journal-title":"Med"},{"key":"ref_65","first-page":"331","article-title":"Stereotactic radiation therapy combined with immunotherapy: Augmenting the role of radiation in local and systemic treatment","volume":"29","author":"Sharabi","year":"2015","journal-title":"Oncology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","article-title":"Abscopal effect: From a rare phenomenon to a new frontier in cancer therapy","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.05.013","article-title":"Combination of SABR with Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study","volume":"114","author":"Zafra","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs. Pembrolizumab Alone on Tumor Response in Patients with Advanced Non\u2013Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_74","first-page":"157","article-title":"Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology","volume":"2","author":"Zhang","year":"2025","journal-title":"Med. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e000732","DOI":"10.1136\/bmjonc-2025-000732","article-title":"Combined immune checkpoint inhibitors and ablative radiotherapy in metastatic cancers: A meta-analysis of prospective clinical trials","volume":"4","author":"Urias","year":"2025","journal-title":"BMJ Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chen, X., Liu, W., Wang, Y., Yue, Z., Wang, J., Liu, Y., Xu, L., and Hu, J. (2026). Synergistic effects of radiotherapy and immunotherapy: Improving oncological outcomes. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1771355"},{"key":"ref_77","first-page":"93","article-title":"Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges","volume":"33","author":"Marijnen","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"115266","DOI":"10.1016\/j.ejca.2025.115266","article-title":"Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis","volume":"218","author":"Acker","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"110910","DOI":"10.1016\/j.radonc.2025.110910","article-title":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"Devnani","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ajco.13688","article-title":"Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy","volume":"19","author":"Guan","year":"2022","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_83","first-page":"17","article-title":"ESMO\u2013ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","volume":"37","author":"Devnani","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and Symptomatic Radiation Necrosis in Patients with Brain Metastases Treated with Stereotactic Radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., and Ma, J. (2022). Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.809304"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Werner, R.S., and Opitz, I. (2021). Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer. Cancers, 13.","DOI":"10.3390\/cancers13246374"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4143\/crt.2022.1460","article-title":"Top Ten Lessons Learned from Trials in Oligometastatic Cancers","volume":"55","author":"Tan","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Parker, C.C., James, N.D., Brawley, C.D., Clarke, N.W., Ali, A., Amos, C.L., Attard, G., Chowdhury, S., Cook, A., and Cross, W. (2022). Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003998"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"103990","DOI":"10.1016\/j.critrevonc.2023.103990","article-title":"The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives","volume":"186","author":"Carconi","year":"2023","journal-title":"Crit. Rev. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102112","DOI":"10.1016\/j.adro.2026.102112","article-title":"Curative Oligometastatic Radiotherapy: Why We Should Redefine Intent When Cure May Be Attainable","volume":"11","author":"Wallach","year":"2026","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Tometich, D.B., Hyland, K.A., Soliman, H., Jim, H.S.L., and Oswald, L. (2020). Living with Metastatic Cancer: A Roadmap for Future Research. Cancers, 12.","DOI":"10.3390\/cancers12123684"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/djab223","article-title":"Survivorship for Individuals Living with Advanced and Metastatic Cancers: National Cancer Institute Meeting Report","volume":"114","author":"AMollica","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_96","first-page":"148","article-title":"Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial","volume":"36","author":"Mou","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2022.05.033","article-title":"Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis","volume":"173","author":"Barry","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2019.08.041","article-title":"Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial","volume":"105","author":"Olson","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.clon.2024.01.007","article-title":"Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial","volume":"36","author":"Mou","year":"2024","journal-title":"Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clon.2020.07.020","article-title":"Supportive Care: An Indispensable Component of Modern Oncology","volume":"32","author":"Berman","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clon.2023.01.015","article-title":"The Rise of Supportive Oncology: A Revolution in Cancer Care","volume":"35","author":"Berman","year":"2023","journal-title":"Clin. Oncol."},{"key":"ref_102","unstructured":"Department of Health and Social Care (2026). National Cancer Plan for England: Delivering World Class Cancer Care."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcpo.2018.02.004","article-title":"Improving the lives of people living with and beyond cancer: Generating the evidence needed to inform policy and practice","volume":"15","author":"Foster","year":"2018","journal-title":"J. Cancer Policy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e057148","DOI":"10.1136\/bmjopen-2021-057148","article-title":"Multimorbidity in patients living with and beyond cancer: Protocol for a scoping review","volume":"12","author":"Ahmad","year":"2022","journal-title":"BMJ Open"},{"key":"ref_105","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2016.72.1373","article-title":"Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship","volume":"35","author":"Nekhlyudov","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/OP.23.00716","article-title":"Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations","volume":"20","author":"Hart","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1200\/JCO.22.02212","article-title":"Evolving Landscape of Metastatic Cancer Survivorship: Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era","volume":"41","author":"Heynemann","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e040808","DOI":"10.1136\/bmjopen-2020-040808","article-title":"Treatable but not curable cancer in England: A retrospective cohort study using cancer registry data and linked data sets","volume":"11","author":"White","year":"2021","journal-title":"BMJ Open"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2023.0416","article-title":"Enhanced supportive care","volume":"85","author":"Monnery","year":"2024","journal-title":"Br. J. Hosp. Med."},{"key":"ref_114","first-page":"376","article-title":"Models, outcomes, barriers, and facilitators of supportive care in cancer: A scoping review","volume":"34","author":"Monnery","year":"2026","journal-title":"Support. Care Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/EDBK_156039","article-title":"The Cancer Survivorship Journey: Models of Care, Disparities, Barriers, and Future Directions","volume":"35","author":"Halpern","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(22)00306-3","article-title":"Improved models of care for cancer survivors","volume":"399","author":"Jefford","year":"2022","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2400084","DOI":"10.1200\/OA-24-00084","article-title":"Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors","volume":"2","author":"Hoang","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"102611","DOI":"10.1016\/j.clinre.2025.102611","article-title":"Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer","volume":"49","author":"Gandini","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-020-01374-w","article-title":"Artificial Intelligence in radiotherapy: State of the art and future directions","volume":"37","author":"Francolini","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1754-9485.13880","article-title":"AI Revolution in Radiology, Radiation Oncology and Nuclear Medicine: Transforming and Innovating the Radiological Sciences","volume":"69","author":"Carriero","year":"2025","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e2400119","DOI":"10.1200\/CCI.24.00119","article-title":"Application of Artificial Intelligence in Symptom Monitoring in Adult Cancer Survivorship: A Systematic Review","volume":"8","author":"Vakili","year":"2024","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e70050","DOI":"10.1002\/cncr.70050","article-title":"Artificial intelligence across the cancer care continuum","volume":"131","author":"Khan","year":"2025","journal-title":"Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Khilar, S., Dembinska-Kenner, A., Hall, H., Syrmos, N., Ligarotti, G.K.I., Plaha, P., Apostolopoulos, V., Chibbaro, S., Barbagallo, G.M.V., and Ganau, M. (2025). Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours. Brain Sci., 15.","DOI":"10.3390\/brainsci15020136"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:49:54Z","timestamp":1786456194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":123,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162584"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162584","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}